Beyond Air (NASDAQ:XAIR) Releases Quarterly Earnings Results, Misses Estimates By $0.20 EPS

Beyond Air (NASDAQ:XAIR) issued its quarterly earnings results on Thursday. The company reported ($11.00) EPS for the quarter, missing analysts’ consensus estimates of ($10.80) by ($0.20), Zacks reports. The business had revenue of $1.77 million for the quarter, compared to analyst estimates of $1.93 million. Beyond Air had a negative net margin of 435.71% and a negative return on equity of 364.17%.

Here are the key takeaways from Beyond Air’s conference call:

• Second-quarter revenue was $1.8 million, essentially flat year over year and sequentially. Gross margin improved to 13%, marking the third consecutive quarter of positive gross profit, although the company still reported a $7.9 million net loss.
• Beyond Air raised $10 million upfront through financing with potential for up to an additional $20 million from warrant exercises, strengthening its ability to fund Gen 2 LungFit PH production, commercial preparations, and international expansion.
• The company said its Gen 2 LungFit PH submission remains on track for potential FDA approval in the second half of 2026, with audits and pilot builds underway. Management described FDA communication as strong but cautioned that timing remains subject to the agency’s review.
• Commercial momentum is building, including a new national group purchasing agreement that gives Beyond Air access to a substantial portion of U.S. hospitals, a pipeline that management says has doubled over the past five to six months, and distribution partnerships spanning more than 40 countries.
• Management reaffirmed 2026 revenue guidance of $8 million and 2027 guidance of $16 million to $18 million; the 2027 outlook includes potential Gen 2 LungFit PH revenue, while the 2026 forecast excludes any contribution from the new system.

Beyond Air Stock Down 8.7%

NASDAQ XAIR opened at $6.32 on Friday. The company has a debt-to-equity ratio of 3.48, a current ratio of 3.80 and a quick ratio of 3.59. Beyond Air has a 12 month low of $5.02 and a 12 month high of $95.60. The company has a market capitalization of $4.56 million, a P/E ratio of -0.09 and a beta of 0.23. The company’s 50 day simple moving average is $7.11 and its 200 day simple moving average is $12.22.

Insider Activity

In other Beyond Air news, CEO Robert Scott Goodman purchased 34,722 shares of the stock in a transaction dated Wednesday, July 29th. The stock was bought at an average price of $5.76 per share, for a total transaction of $199,998.72. Following the transaction, the chief executive officer directly owned 34,822 shares in the company, valued at $200,574.72. This represents a 34,722.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 9.99% of the company’s stock.

Hedge Funds Weigh In On Beyond Air

Hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its position in shares of Beyond Air by 1.5% during the 2nd quarter. Geode Capital Management LLC now owns 838,319 shares of the company’s stock valued at $144,000 after acquiring an additional 12,598 shares during the last quarter. Osaic Holdings Inc. boosted its position in shares of Beyond Air by 26.4% in the 2nd quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock worth $29,000 after purchasing an additional 34,000 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Beyond Air during the third quarter worth $48,000. Finally, Alyeska Investment Group L.P. bought a new stake in Beyond Air in the third quarter valued at about $1,753,000. 31.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Beyond Air in a report on Tuesday, July 21st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Beyond Air currently has a consensus rating of “Hold” and an average target price of $200.00.

Beyond Air Company Profile

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.